Santaris Pharma

RNA medicines for the 21st century.

Forbion Capital Partners supported Santaris Pharma since 2006 leading its Series B financing round and in all subsequent rounds.

Santaris Pharma was acquired by Roche in August 2014 for up to $450 million.